Rare Disease Discussions

About Rare Disease Discussions

Conversations with the leaders advancing rare disease care. Rare Discussions is CheckRare's flagship interview podcast featuring conversations with leading physicians, researchers, patient advocates, and industry experts. These episodes explore advances in diagnosis, treatment, research, and patient care across the rare disease landscape. Whether highlighting groundbreaking therapies or sharing expert clinical perspectives, Rare Discussions highlights the experts who are shaping the future of rare disease medicine.

Publisher

CheckRare Editors

Category

health & fitness

Language

en

Explicit

Yes

First episode

15 Apr 2020

Latest episode

19 Oct 2026

Latest episodes

49 of 201 episodes have a transcript.

1. 

   19 Oct 2026TRANSCRIPT

   Breakthrough Therapy Designation to Cimzia for Antiphospholipid Syndrome

   Jane Salmon, MD, Professor of Medicine at Weill Cornell Medical College, discusses Cimzia's breakthrough designation for antiphospholipid syndrome, offering hope for preventing serious pregnancy complications in an interview.

2. 

   16 Oct 2026TRANSCRIPT

   FDA Approves Gazyva for Idiopathic Nephrotic Syndrome, Offering a New Treatment Option

   Pediatric nephrologist Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva, offering a new treatment option for childhood idiopathic nephrotic syndrome.

3. 

   16 Oct 2026TRANSCRIPT

   New Stem Cell Method Could Advance Research Into Spinal Muscular Atrophy

   Kyle Loh, PhD, Associate Professor at Stanford Medicine, explains a new stem cell method that generates motor neurons, advancing spinal muscular atrophy research.

Inside a recent episode

Breakthrough Therapy Designation to Cimzia for Antiphospholipid Syndrome

Published 19 Oct 2026 · Transcript excerpt

[…] It's a drug that does not cross the placenta because it doesn't have an IgG piece. It doesn't bind to FCRN. And that's why we selected it. The dose we use is the same dose that is approved for rheumatoid arthritis and Crohn's disease. We didn't dose adjust. And patients got drug from week eight. till week 28. Half-life is 14 days, so generally by the time they delivered, there was probably, even if there was a minuscule amount that got into the baby, though it's generally unmeasurable, it would have been cleared. And the issue about TNF treatment during pregnancy, it's not teratogenic, it's not dangerous, but if you use a TNF blocker with an FCP, the vaccine schedule in the babies have to be changed because they're mildly immunocompromised till they clear all the TNF antibody. […]

Who has been a guest on Rare Disease Discussions

Names identified in recent episode analyses. Showing up to five guests.

• Jane Salmon
• Keisha L Gibson
• Kyle Loh
• Jorge Nieva
• Michael Benatar

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

3 ratings

Spotify

5.0 / 5

1 ratings

Podcast Authority Score: 47 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

67

Social presence

0

YouTube

0

Engagement

68